European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment - update 2026
Alexander Stratigos(National and Kapodistrian University of Athens), Josep Malvehy(Universitat de Barcelona), Brigitte Dréno(Nantes Université), Véronique Bataille(King's College London), Ricardo Vieira(Hospitais da Universidade de Coimbra), D. Moreno‐Ramírez(Hospital Universitario Virgen Macarena), Célèste Lebbé(Inserm), Petr Arenberger(Charles University), Philippe Saïag(Université de Versailles Saint-Quentin-en-Yvelines), Roland Kaufmann(Robert Koch Institute), Catherine Harwood(Queen Mary University of London), Axel Hauschild(University Hospital Schleswig-Holstein), Myrto Trakatelli(Papageorgiou General Hospital), Alexander M.M. Eggermont(University Medical Center Utrecht), Christoph Höeller(Medical University of Vienna), Maria Concetta Fargnoli(University of L'Aquila), Aimilios Lallas(Aristotle University of Thessaloniki), Paul Lorigan(Manchester Academic Health Science Centre), V. del Mármol(Université Libre de Bruxelles), Lidija Kandolf Sekulović(Military Medical Academy), Alexander C. J. van Akkooi(The University of Sydney), Clio Dessinioti(Andreas Sygros Hospital), Ulrike Leiter(University of Tübingen), Luca Tagliaferri(Agostino Gemelli University Polyclinic), Iris Zalaudek(Azienda Sanitaria Universitaria Integrata di Trieste), Reinhard Dummer(University Hospital of Zurich), Ketty Peris(Università Cattolica del Sacro Cuore), Giovanni Pellacani(Sapienza University of Rome), Nicole WJ Kelleners-Smeets(Maastricht University Medical Centre), Claus Garbe(University of Tübingen)
Cited by 100
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k